Cardiomyocyte gene delivery

Cardiomyocyte gene delivery" is not a molecule, protein, or traditional therapeutic target; rather, it refers to the broad technique or field of methods used to transfer transgenes into cardiomyocytes (heart muscle cells) for applications such as gene therapy. It encompasses a range of viral (e.g., adeno-associated virus, adenovirus) and non-viral (e.g., nanoparticles) vector systems and delivery approaches (e.g., intramyocardial injection, transvascular delivery, pericardial injection) intended to modify cardiomyocyte function or promote heart regeneration, especially in settings such as heart failure or myocardial infarction. "Cardiomyocyte gene delivery" is a research and therapeutic method, not a specific gene, protein, receptor, enzyme, or pharmacological target[1][2][3][4][5].